1. Medical adhesive allergens: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2018.
- Author
-
Atwater AR, Bembry R, Liu B, Warshaw EM, DeKoven JG, Silverberg JI, Taylor JS, Zug KA, Houle MC, Belsito DV, Maibach HI, Reeder MJ, Sasseville D, Dunnick C, Fowler JF Jr, Pratt MD, and DeLeo VA
- Subjects
- Adhesives adverse effects, Cross-Sectional Studies, Female, Humans, Male, North America epidemiology, Patch Tests methods, Retrospective Studies, Allergens adverse effects, Dermatitis, Allergic Contact diagnosis, Dermatitis, Allergic Contact epidemiology, Dermatitis, Allergic Contact etiology
- Abstract
Background: Identification of allergens causing medical adhesive contact allergy is difficult., Objective: To characterize the demographics, clinical characteristics, patch test results, and occupational data for North American Contact Dermatitis Group patients with medical adhesive contact allergy., Methods: A retrospective study of 43,722 North American Contact Dermatitis Group patients patch tested from 2001 to 2018 with medical adhesive (tapes/bandaids/adhesive aids/suture glue) sources, positive patch test results, and final primary diagnoses of allergic contact dermatitis., Results: In total, 313 (0.7%) patients met the inclusion criteria. Compared with other patients with final primary diagnoses of allergic contact dermatitis, patients with a medical adhesive allergy were less likely to be male (odds ratio, 0.58; 95% CI, 0.45-0.77) and/or aged >40 years (odds ratio, 0.76; 95% CI, 0.60-0.96). The most common North American Contact Dermatitis Group screening series allergens were colophony (80.7%), balsam of Peru (3.9%), 2-hydroxyethyl methacrylate (2.7%), and carba mix (2.7%). One-fourth of the patients (79/313, 25.2%) had positive patch test reactions to supplemental allergens/materials, and 54 (17.3%) of the 313 patients only had reactions to supplemental allergens/materials., Limitations: Results of comprehensive patch testing may be prone to referral population selection bias and may not be representative of the general dermatology population., Conclusion: Colophony was the most common allergen. Supplemental allergens and materials should be tested in the evaluation of a suspected medical adhesive contact allergy., Competing Interests: Conflicts of interest Dr Taylor has consulted for Johnson & Johnson, Bayer, Kao Brands, and Equinox Group; received royalties from Decision Support in Medicine; owns noncontrolling shares of common stock in AstraZeneca, Cigna, Johnson & Johnson, Merck, and Opko Health; and is a member of the Steering Committee of the Cosmetic Ingredient Review; a nondependent child is an employee of Pfizer. Dr Reeder is the American Contact Dermatitis Society Contact Allergy Management Program Director. Drs Sasseville and Reeder receive royalties from UpToDate (Wolters Kluwer Health). Dr Atwater received the Pfizer Independent Grant for Learning & Change, has consulted for Henkel, and is currently employed by Eli Lilly and Company. Dr Warshaw has received an investigator-initiated grant from and served as a consultant for Wen by Chaz Dean and served as a consultant for Noven Pharmaceuticals. Drs Bembry, Liu, DeKoven, Silverberg, Zug, Houle, Belsito, Maibach, Dunnick, Fowler, Pratt, and DeLeo have no conflicts of interest to declare., (Copyright © 2021 American Academy of Dermatology, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF